How aggressive should we be in patients with stage IV colorectal cancer?

被引:92
作者
Kuo, LJ
Leu, SY
Liu, MC
Jian, JJM
Cheng, SH
Chen, CM
机构
[1] Koo Fdn Sun Yat Sen Canc Ctr Hosp, Dept Surg, Div Colorectal Surg, Taipei 112, Taiwan
[2] Koo Fdn Sun Yat Sen Canc Ctr Hosp, Dept Med Oncol, Div Colorectal Surg, Taipei 112, Taiwan
[3] Koo Fdn Sun Yat Sen Canc Ctr Hosp, Dept Radiat Oncol, Div Colorectal Surg, Taipei 112, Taiwan
[4] Koo Fdn Sun Yat Sen Canc Ctr Hosp, Dept Res, Div Colorectal Surg, Taipei 112, Taiwan
关键词
D O I
10.1007/BF02660770
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
PURPOSE: The prognosis for metastatic colorectal cancer is grave. Whether to perform surgical resection or palliative treatment remains controversial for this advanced disease. In this retrospective study, we collected data from patients with Stage IV colorectal cancer to identify prognostic factors for predicting selection criteria for surgical treatment in patients with metastatic disease. METHODS: A retrospective chart review was performed for patients treated from 1992 to 1999 from the Koo Foundation Sun Yat-Sen Cancer Center Tumor Registry. Seventy-four patients were identified as having Stage IV disease at the time of diagnosis. Data concerning the patients' demographics, laboratory results, operative procedure, mortality, morbidity, and survival were collected. Independent variables and survival time were analyzed by the independent t-test method. The difference was considered statistically significant at P < 0.05. RESULTS: Overall survival time for the patients with Stage IV colorectal cancer was 16.1 months. Survival in the curative resection group was significantly longer than that in the noncurative group (31.9 vs. 12.7; P < 0.016). The operative mortality and morbidity rates were 5.6 percent (4 of 71) and 21.1 percent (15 of 71), respectively. The two most common complications were leakage at the site of anastomosis and urinary tract infection. Based on these results, we conclude that patients older than 65 years, with metastases at multiple sites, intestinal obstruction, preoperative carcinoembryonic antigen level greater than or equal to 500 ng/ml, lactate dehydrogenase 350 units/liter, hemoglobin < 10 mg/dl, or hepatic parenchymal replacement by tumor > 25 percent have poor prognosis for surgical intervention. CONCLUSION: Whether to perform primary tumor resection in patients with asymptomatic Stage IV colorectal cancer remains controversial; however, the more aggressively we perform radical resection and metastasectomy to selected patients, the more survival benefits the patients obtain.
引用
收藏
页码:1646 / 1652
页数:7
相关论文
共 34 条
[1]   The importance of visceral metastasectomy in colorectal cancer [J].
Adam, R .
ANNALS OF ONCOLOGY, 2000, 11 :29-36
[2]   Randomized multicenter phase II study comparing a combination of fluorouracil and folinic acid and alternating irinotecan and oxaliplatin with oxaliplatin and irinotecan in fluorouracil-pretreated metastatic colorectal cancer patients [J].
Bécouarn, Y ;
Gamelin, E ;
Coudert, B ;
Négrier, S ;
Pierga, JY ;
Raoul, JL ;
Provençal, J ;
Rixe, O ;
Krisch, C ;
Germa, C ;
Bekradda, M ;
Mignard, D ;
Mousseau, M .
JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (22) :4195-4201
[3]   SURGICAL-MANAGEMENT OF THE ACUTELY OBSTRUCTED COLON - A REVIEW OF 127 CASES [J].
BUECHTER, KJ ;
BOUSTANY, C ;
CAILLOUETTE, R ;
COHN, I .
AMERICAN JOURNAL OF SURGERY, 1988, 156 (03) :163-168
[4]   Malignant colorectal obstruction treated by means of self-expanding metallic stents:: Effectiveness before surgery and in palliation [J].
Camúñez, F ;
Echenagusia, A ;
Simó, G ;
Turégano, F ;
Vázquez, J ;
Barreiro-Meiro, I .
RADIOLOGY, 2000, 216 (02) :492-497
[5]   Trends in long-term survival following liver resection for hepatic colorectal metastases [J].
Choti, MA ;
Sitzmann, JV ;
Tiburi, MF ;
Sumetchotimetha, W ;
Rangsin, R ;
Schulick, RD ;
Lillemoe, KD ;
Yeo, CJ ;
Cameron, JL .
ANNALS OF SURGERY, 2002, 235 (06) :759-765
[6]  
Cole, 2000, Colorectal Dis, V2, P282, DOI 10.1046/j.1463-1318.2000.00180.x
[7]   Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer [J].
Cunningham, D ;
Pyrhönen, S ;
James, RD ;
Punt, CJA ;
Hickish, TF ;
Heikkila, R ;
Johannesen, TB ;
Starkhammar, H ;
Topham, CA ;
Awad, L ;
Jacques, C ;
Herait, P .
LANCET, 1998, 352 (9138) :1413-1418
[8]  
*DEP HLTH, 1998, CANC REG ANN REP
[9]   Oxaliplatin as single agent in previously untreated colorectal carcinoma patients: A phase II multicentric study [J].
Diaz-Rubio, E ;
Sastre, J ;
Zaniboni, A ;
Labianca, R ;
Cortes-Funes, H ;
de Braud, F ;
Boni, C ;
Benavides, M ;
Dallavalle, G ;
Homerin, M .
ANNALS OF ONCOLOGY, 1998, 9 (01) :105-108
[10]   Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer - Analysis of 1001 consecutive cases [J].
Fong, Y ;
Fortner, J ;
Sun, RL ;
Brennan, MF ;
Blumgart, LH .
ANNALS OF SURGERY, 1999, 230 (03) :309-318